



Model List of Essential Medicines

Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Cyanocobalamin

Section	Indications
Antianaemia medicines	Anaemias or other erythrocyte disorders

Dabigatran

Section	Indications
Medicines affecting coagulation Oral > Solid: 110 mg; 150 mg	Venous thromboembolism Other specified atrial fibrillation

Dalteparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism

Darbepoetin alfa

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Deferasirox

Section	Indications
Other medicines for haemoglobinopathies	Other specified sickle cell disorders or other haemoglobinopathies
Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg	Thalassaemias
Oral > Solid > tablet: 90 mg; 180 mg; 360 mg	Therapeutic equivalent to deferoxamine for Thalassaemias

Deferiprone

Section	Indications
Other medicines for haemoglobinopathies	Therapeutic equivalent to deferasirox for Other specified sickle cell disorders or other haemoglobinopathies
	Therapeutic equivalent to deferasirox for Thalassaemias
	Thalassaemias

Deferoxamine

Section	Indications
Other medicines for haemoglobinopathies	Other specified sickle cell disorders or other haemoglobinopathies
Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)	Thalassaemias

Desmopressin

Section	Indications
Medicines affecting coagulation	Haemophilia A
Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)	Von Willebrand disease
Local > Nasal > Spray: 10 µg per dose (acetate)	

Edoxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism
	Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Enoxaparin

Section	Indications
Medicines affecting coagulation Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule	Acute ischaemic heart disease Venous thromboembolism

Epoetin alfa

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Epoetin theta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Erythropoiesis-stimulating agents

Section	Indications
Antianaemia medicines Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe	Anaemia due to chronic disease

Ferrous salt

Section	Indications
Antianaemia medicines Oral > Liquid: 25 mg per mL iron (as sulfate) Oral > Solid: 60 mg iron	Iron deficiency anaemia

Ferrous salt + folic acid

Section	Indications
Antianaemia medicines Oral > Solid: 60 mg iron + 2.8 mg Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg	Iron deficiency anaemia Clefts of lip, alveolus or palate Iron deficiency anaemia Anencephaly or similar anomalies Spina bifida

Folic acid

Section	Indications
Antianaemia medicines Oral > Solid: 1 mg tablet; 5 mg tablet Oral > Solid: 400 µg	Folate deficiency anaemia Anencephaly or similar anomalies Spina bifida Cephalocele

Heparin sodium

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule; 20000 IU per mL in 1 mL ampoule; 5000 IU per mL in 1 mL ampoule	Acute ischaemic heart disease Unstable angina Venous thromboembolism

Hydroxocobalamin

Section	Indications
Antianaemia medicines Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)	Megaloblastic anaemia due to vitamin B12 deficiency

Hydroxycarbamide (hydroxyurea)

Section	Indications
Other medicines for haemoglobinopathies Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg	Other specified sickle cell disorders or other haemoglobinopathies

Methoxy polyethylene glycol-epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Nadroparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism

Phytomenadione

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule Oral > Solid: 10 mg tablet	Haemorrhagic disorder due to other specified circulating anticoagulants Haemorrhagic or haematological disorders of fetus or newborn

Protamine sulfate

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule	Haemorrhagic disorder due to other specified circulating anticoagulants

Rivaroxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Tranexamic acid

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Haemorrhage, not elsewhere classified

Warfarin

Section	Indications
Medicines affecting coagulation Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)	Other specified diseases of arteries or arterioles Cerebral ischaemic stroke due to embolic occlusion Venous thromboembolism Atrial fibrillation